Contact
searchSearch
HMP Global
Login
Quiz

Early Switch to Camizestrant at ESR1 Mutation Emergence in HR-Positive, HER2-Negative Advanced Breast Cancer

12/12/2025

Related Content

Sami Diab, MD
Videos
Updated NCCN Guidelines Strengthen Support for Breast Cancer Index® in Extended Endocrine Therapy Decision-Making
01/23/2026
Sami Diab, MD
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent...
01/23/2026
Oncology
Joseph Sparano, MD
Conference Coverage
Multimodal AI Model Strengthens Prognostic Accuracy for Late Distant Recurrence in HR-Positive, HER2-Negative Early Breast Cancer
12/18/2025
Joseph Sparano, MD
Joseph Sparano, MD, discusses new findings from the TAILORx multimodal AI analysis, which identified that multimodal AI models, particularly the ICM+ model, significantly outperformed traditional models for predicting late distant recurrence...
Joseph Sparano, MD, discusses new findings from the TAILORx multimodal AI analysis, which identified that multimodal AI models, particularly the ICM+ model, significantly outperformed traditional models for predicting late distant recurrence...
Joseph Sparano, MD, discusses...
12/18/2025
Oncology
Aditya Bardia, MD
Conference Coverage
Giredestrant Improves Survival Outcomes in ER-Positive, HER2-Negative Early-Stage Breast Cancer
12/18/2025
Aditya Bardia, MD
Aditya Bardia, MD, discusses results from the phase 3 lidERA trial showing giredestrant significantly improved invasive disease-free survival compared to standard endocrine therapy for patients with ER-positive, HER2-negative early-stage...
Aditya Bardia, MD, discusses results from the phase 3 lidERA trial showing giredestrant significantly improved invasive disease-free survival compared to standard endocrine therapy for patients with ER-positive, HER2-negative early-stage...
Aditya Bardia, MD, discusses...
12/18/2025
Oncology
Conference Coverage
Imlunestrant Plus Abemaciclib for HR-Positive, HER2-Negative Advanced Breast Cancer: EMBER-3 Trial
12/12/2025
Stephanie Holland
Updated results from the EMBER-3 trial show that imlunestrant, alone or with abemaciclib, provides clinically meaningful efficacy and manageable safety among previously treated patients with HR-positive, HER2-negative advanced breast cancer,...
Updated results from the EMBER-3 trial show that imlunestrant, alone or with abemaciclib, provides clinically meaningful efficacy and manageable safety among previously treated patients with HR-positive, HER2-negative advanced breast cancer,...
Updated results from the EMBER-3...
12/12/2025
Oncology

Recent News

FDA Approval
FDA Approves Simplified Once-Monthly Amivantamab Plus Hyaluronidase Regimen for First-Line EGFR-Mutated Advanced NSCLC
02/18/2026
Stephanie Holland
The FDA has approved a new, simplified once-monthly dosing schedule for amivantamab plus hyaluronidase when administered in combination with lazertinib for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer.
The FDA has approved a new, simplified once-monthly dosing schedule for amivantamab plus hyaluronidase when administered in combination with lazertinib for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer.
The FDA has approved a new,...
02/18/2026
Oncology
FDA Alerts
FDA Grants Breakthrough Therapy Designation to Subcutaneous Amivantamab in HPV-Unrelated Head and Neck Squamous Cell Carcinoma
02/18/2026
Stephanie Holland
Based on data from the phase 1b/2 OrigAMI-4 study, the FDA has granted breakthrough therapy designation to amivantamab plus hyaluronidase for patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma.
Based on data from the phase 1b/2 OrigAMI-4 study, the FDA has granted breakthrough therapy designation to amivantamab plus hyaluronidase for patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma.
Based on data from the phase...
02/18/2026
Oncology
Kelly E. McCann, MD, PhD
News
OLN Great Debates: Navigating Evolving Evidence and Treatment Decisions in Breast Oncology
02/17/2026
Kelly McCann, MD, PhD
For clinicians treating breast cancer, staying current has never been more challenging. New trial data, biomarker-driven strategies, and therapeutic options continue to emerge at a rapid pace, yet translating that evidence into confident,...
For clinicians treating breast cancer, staying current has never been more challenging. New trial data, biomarker-driven strategies, and therapeutic options continue to emerge at a rapid pace, yet translating that evidence into confident,...
For clinicians treating breast...
02/17/2026
Oncology
News
Pirtobrutinib Demonstrates Promise in Relapsed or Refractory Marginal Zone Lymphoma
02/17/2026
Stephanie Holland
Results from the phase 1/2 BRUIN study demonstrated that pirtobrutinib showed promising efficacy and tolerable safety in heavily pretreated patients with relapsed or refractory marginal zone lymphoma.
Results from the phase 1/2 BRUIN study demonstrated that pirtobrutinib showed promising efficacy and tolerable safety in heavily pretreated patients with relapsed or refractory marginal zone lymphoma.
Results from the phase 1/2 BRUIN...
02/17/2026
Oncology
News
Nivolumab Plus Chemotherapy Maintains Survival Advantage in Gastroesophageal Adenocarcinoma
02/12/2026
Stephanie Holland
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from...
02/12/2026
Oncology
News
Iopofosine I 131 Shows Durable Responses in Heavily Pretreated Waldenström Macroglobulinemia
02/12/2026
Emily Estrada
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug...
02/12/2026
Radiopharmaceutical Education Institute
News
Maintenance Palbociclib Extends PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer
02/11/2026
Stephanie Holland
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA...
02/11/2026
Oncology
News
First-Line Toripalimab Improves PFS in Advanced Melanoma Predominantly of Acral Subtype
02/11/2026
Stephanie Holland
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3...
02/11/2026
Oncology
FDA Approval
FDA Approves Pembrolizumab-Based Regimens for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
02/10/2026
Emily Estrada
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA...
02/10/2026
Oncology
News
Post-Treatment Plasma ctDNA Accurately Identifies Recurrence in Muscle-Invasive Bladder Cancer
02/09/2026
Stephanie Holland
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a...
02/09/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use